Why did I choose diagnostics?
I am an optimist. I see possibility in everything we do. Today we are delivering clinical utility—real value—by changing clinical practice.
Real People,
Real Science,
Real Answers.
Chief Executive Officer and
Chairman of the Board
This is the Age of Evidence.
Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek.

Veracyte gives patients a clearer path for the future.

We are leading in the Age of Evidence.
our impact
The Age
of Evidence
Veracyte's genomic tests have the potential to save billions of dollars each year in unnecessary surgery costs.
Learn More >
Now Covered by Medicare
Genomic test is first to gain Medicare coverage for use in lung cancer screening and diagnosis.
learn more >
Evidence Equals Impact
Hear Veracyte CEO Bonnie Anderson discuss in a "Business Rockstars" interview how the company’s genomic tests are transforming patient care.

watch now >

latest news
news and updates
Sep 25, 2017
Veracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMA

learn more >
Sep 19, 2017
Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together

learn more >
Sep 19, 2017
Veracyte Launches Campaign to Save Lives through Early Screening for Lung Cancer

learn more >